ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.
Age range
18 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only)
Timeframe: From first dose of study intervention to 28 days post first dose
Number of participants with Adverse Events and Serious Adverse Events
Timeframe: From first dose of study intervention up to 37 days after the last dose of study treatment
Number of participants with Adverse Events leading to discontinuation of study intervention
Timeframe: From first dose of study intervention up to 37 days after the last dose of study treatment
Clinically significant changes from baseline in vital signs.
Timeframe: From first study dose up to 37 days after the last dose of study treatment
Clinically significant changes from baseline in physical examination.
Timeframe: From first dose of study intervention up to 37 days after the last dose of study treatment
Clinically significant changes from baseline in ECOG PS.
Timeframe: From first dose of study intervention up to 37 days after the last dose of study treatment
AstraZeneca Clinical Study Information Center
Clinically significant changes from baseline in ECGs.
Timeframe: From first dose of study intervention up to 37 days after the last dose of study treatment
Clinically significant changes from baseline in laboratory parameters.
Timeframe: From first dose of study intervention up to 37 days after the last dose of study treatment
Proportion of participants achieving a ≥50% decrease in PSA from baseline (PSA50) (Part B only)
Timeframe: From first dose of study intervention up to 14 days after the last dose of study treatment